Form 4: Tarsus CEO Azamian Reports RSU Vesting, Share Ownership

Tarsus Pharmaceuticals CEO Bobak R. Azamian reported the settlement of vested Restricted Stock Units and updated his beneficial ownership of company common stock.

Summary

• Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reported transactions related to his beneficial ownership.
• On March 15, 2026, Azamian acquired 66,274 shares of Tarsus Common Stock through the settlement of vested Restricted Stock Units (RSUs).
• Following these transactions, Azamian directly owns 68,024 shares of Common Stock.
• Additionally, Azamian indirectly owns 857,991 shares of Common Stock through the Bobak Azamian Living Trust.
• A total of 11,300 RSUs from a March 9, 2022 grant fully vested and were converted, leaving 0 RSUs remaining from this grant.
• From a March 8, 2023 RSU grant, 16,975 units vested and were converted, with 16,975 RSUs remaining to vest in future periods.
• From a March 7, 2024 RSU grant, 23,121 units vested and were converted, with 46,243 RSUs remaining to vest in future periods.
• From a March 5, 2025 RSU grant, 14,878 units vested and were converted, with 44,634 RSUs remaining to vest in future periods.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects routine executive compensation and continued insider ownership, which can be a sign of management confidence, but offers no new operational or financial insights.

Positives

• CEO Bobak R. Azamian continues to hold a significant stake in the company, with 68,024 shares directly and 857,991 shares indirectly, totaling 926,015 shares.
• The vesting of RSUs indicates the ongoing compensation and retention of key management.

Future Outlook

The filing indicates future vesting dates for various Restricted Stock Unit grants extending through March 15, 2029, subject to the reporting person's continuous service, suggesting ongoing executive retention.

Industry Context

StockSavvy.ai notes that routine insider transaction reports like this Form 4 are common across all industries, particularly for executives receiving equity compensation. The vesting of RSUs is a standard practice for retaining key talent in the highly competitive biotechnology and pharmaceutical sectors, where long-term incentives are crucial for aligning management interests with shareholder value creation. This filing does not provide specific industry-related performance metrics or strategic updates.

Comparison to Industry Standards

• This Form 4 reports standard RSU vesting and conversion, which is a common form of executive compensation in the pharmaceutical industry.
• Companies like Pfizer, Moderna, and Johnson & Johnson frequently use similar equity-based incentives to align executive interests with long-term company performance.
• The specific number of shares and vesting schedules are typical for a CEO of a publicly traded pharmaceutical company, reflecting a compensation structure designed to reward sustained service and performance.

Stakeholder Impact

• Shareholders: Provides transparency on executive stock ownership and compensation, potentially signaling management's alignment with shareholder interests.
• Employees: Reflects standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• Continued vesting of remaining Restricted Stock Units on March 15th of 2027, 2028, and 2029, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of insider stock transactions related to RSU vesting and does not contain any new material information that would warrant a change in investment recommendation. It confirms ongoing executive equity ownership, which is generally a neutral to slightly positive signal, but lacks operational or financial data to drive a 'buy' or 'sell' decision.

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU Vesting, Bobak Azamian, CEO, Director, Beneficial Ownership